Lactulak

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Lactulak

This foundational section introduces Lactulak by defining its identity, essential composition, and high-level mechanism of action, strictly adhering to classification and general purpose.

Property Description
Active Ingredient Lactulose
Form Oral solution (syrup)
Pharmacological Class Osmotic Laxative
General Purpose Bowel regularity support
Origin Synthetic Disaccharide

What Type of Medicine is Lactulak?

Lactulak is a trade designation for a medicinal product whose active component is the substance Lactulose. Lactulose is chemically classified as a synthetic disaccharide, a type of sugar molecule created from fructose and galactose which is not absorbed by the human body in the small intestine. Pharmacologically, the medicine is categorized as an osmotic laxative. This places it within the class of non-stimulant laxatives, differentiating its gentle approach from agents that chemically force intestinal muscle contraction.


Composition and Pharmaceutical Form

Lactulak is typically prepared as an oral solution or syrup, a viscous, liquid dosage form intended for consumption via the oral route. The essential composition involves the active ingredient Lactulose dissolved in an aqueous base. This water-based preparation ensures the necessary hydrophilic nature of the non-absorbable sugar is maintained until it reaches the large intestine. This approach is utilized in managing chronic conditions, as Lactulose is effective in increasing stool frequency and improving consistency. The medicine helps the body improve stool passage gently and effectively, a benefit widely clinically recognized for supportive management of conditions requiring soft stools.


General Purpose and Fundamental Action

The general purpose of Lactulak is to assist in maintaining bowel regularity by facilitating the natural movement of matter through the digestive system. Its fundamental action relies on the principle of osmosis, where the unabsorbed Lactulose draws water into the colon, thereby increasing the volume and significantly softening the stool. A secondary mechanism involves the fermentation of Lactulose by colon bacteria, which produces a mild change in acidity that helps the body manage specific circulating waste products like ammonia. This dual action is particularly relevant for patients requiring a non-irritating, consistent means of achieving relief.

What side effects are possible with Lactulak?

Possible Side Effects and Safety Information

The safety profile for Lactulak, which contains the active ingredient Lactulose, is characterized by expected adverse reactions primarily affecting the gastrointestinal system, as documented in official regulatory labeling.

Adverse Reaction Frequency

Adverse reactions are classified by frequency according to regulatory standards, with the most common effects related to the medicine's osmotic action:

  • Very Common (Affecting ge 1 in 10 patients): Diarrhoea.
  • Common (Affecting ge 1 in 100 to < 1 in 10 patients): Flatulence, abdominal pain, nausea, and vomiting.
  • Uncommon: Electrolyte imbalance, such as low potassium (hypokalemia), which is specifically linked to excessive or prolonged diarrhoea.

Flatulence and intestinal cramps often occur during the first few days of treatment and are typically transient, lessening as treatment continues. Long-term, high-dose use carries a risk of fluid and electrolyte disturbance if diarrhoea is not managed.

Serious Adverse Reactions and Safety Restrictions

While uncommon, the primary serious safety concern is the potential for severe electrolyte imbalance (e.g., fluid loss) resulting from unadjusted, excessive, or chronic high-dose use leading to persistent diarrhoea. Furthermore, the official label includes a warning about a theoretical hazard during specific colon procedures involving electrocautery, due to the accumulation of hydrogen gas.

Lactulak is contraindicated for individuals with Galactosaemia or acute conditions like gastro-intestinal obstruction or digestive perforation. For older or debilitated patients receiving chronic therapy for more than six months, regulatory documents indicate the need for periodic control of serum electrolytes.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory information describes the overdose profile of Lactulak primarily based on the effects of excessive laxation.


Documented Overdose Manifestations

When excessive doses are taken, the most common documented clinical manifestations are gastrointestinal in nature:

  • Diarrhea
  • Abdominal Cramps

Serious Risks and Required Actions

The most serious risk associated with overdosage is not the medication itself, but the consequences of excessive bowel movements. Prolonged diarrhea can lead to significant:

  • Fluid Loss (Dehydration)
  • Electrolyte Imbalances (such as hypokalemia or hypernatremia)

When to seek immediate medical help: Urgent medical attention is required if signs of severe dehydration or a significant electrolyte imbalance are present following a suspected overdose.

Management and Regulatory Guidance

Official regulatory guidance specifies that in the event of overdosage, the treatment should be terminated (i.e., stop taking the medication). Management is symptomatic and supportive, focusing on correcting any fluid and electrolyte losses. It is important to note that no specific antidote for Lactulak is listed in regulatory documentation.

Therapeutic Uses of Lactulak

What Lactulak Treats: Main Uses and Benefits

Lactulose, the active ingredient in Lactulak, is commonly used to help with managing two main therapeutic areas: symptoms related to physical discomfort and conditions characterized by periods of heightened symptoms related to advanced liver disease. This medication is considered relevant for easing chronic and habitual constipation.

It helps soften stools and may assist with maintaining functional stability related to bowel movements, which contributes to easing the overall symptom load related to physical discomfort. This is often used in scenarios where additional management of discomfort is required, such as where a soft stool is considered relevant for clinical purposes.

The medication is applied in addressing hepatic encephalopathy (HE), a condition characterized by periods of heightened symptoms related to advanced liver disease. In this context, it contributes to easing symptoms linked to systemic imbalance. It plays a role in managing systemic imbalance, supporting patients during episodes of heightened discomfort and may assist with maintaining functional stability.

The main therapeutic domains include managing symptoms related to physical discomfort and systemic imbalance.

Lactulose supports patients during episodes of heightened discomfort and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: May Assist with Relief for Symptoms related to Physical Discomfort

Regulatory References

  1. NIH MedlinePlus overview of Lactulose

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Lactulak?

This information strictly follows official government regulatory documents (e.g., FDA, EMA) defining the population eligible for Lactulose (the active ingredient in Lactulak) use.

Contraindications (Must Not Use)

  • Hereditary Metabolic Disorders: Individuals with galactosaemia or those requiring a low-galactose diet must not use this medicine due to the presence of residual sugar components.
  • Acute Gastrointestinal Conditions: Use is strictly contraindicated in the presence of gastrointestinal obstruction or blockages, and in cases of or risk of gastrointestinal perforation.

Restricted or Conditional Use

  • Diabetes Mellitus: Patients with diabetes should use the medicine with caution. High doses, such as those used for hepatic encephalopathy, may require adjustment of anti-diabetic therapy due to the residual sugar content.
  • Age and Long-term Use: Geriatric or debilitated patients receiving the solution for more than six months require periodic serum electrolyte measurements.
  • Pregnancy and Lactation: Use during pregnancy and by nursing mothers should be approached with caution and only if clearly necessary, as there is a lack of sufficient human safety data in these groups.
  • Pediatric Population: While eligible, use in infants and small children often requires special prescription and monitoring due to the potential to disrupt normal stool reflexes.

What should I know about interactions with other medicines?

Lactulak (lactulose) may interact with certain other medicines, potentially reducing its effectiveness or increasing the risk of side effects. It is essential to inform your doctor or pharmacist about all prescription and non-prescription medications, vitamins, and herbal supplements you are currently taking.

Key Drug Interactions

  • Other Laxatives: Concomitant use with other laxatives is generally not recommended as it significantly increases the risk of side effects such as diarrhea, which can lead to dehydration and electrolyte imbalance (e.g., low potassium levels, known as hypokalemia).

  • Certain Antacids: Antacids, particularly those containing aluminum hydroxide or magnesium, can decrease the therapeutic effect of Lactulak by raising the pH in the colon, which interferes with the conversion of lactulose into its active form.

  • Certain Anti-infective Agents (Antibiotics): Certain antibiotics, such as neomycin, can eliminate the bacteria necessary to break down lactulose in the colon, thereby reducing Lactulak's effectiveness, especially when used for hepatic encephalopathy.

  • Diuretics and Corticosteroids: Medications that can lower potassium levels (e.g., thiazide diuretics or corticosteroids) should be used with caution, as the potential for potassium depletion is increased when combined with Lactulak, particularly if the patient develops diarrhea. Close monitoring of blood electrolyte levels may be required.

Drug Class Potential Interaction Effect Clinical Advice
Other Laxatives Increased risk of diarrhea and electrolyte imbalance. Use only under medical guidance.
Certain Antacids Decreased effectiveness of Lactulak. Avoid or stagger administration times.
Potassium-Lowering Agents Increased risk of hypokalemia. Monitor electrolyte levels closely.

Mechanism of Action

The mechanism of Lactulak is exclusively peripheral, operating within the gastrointestinal tract through two distinct, co-occurring processes: physical water regulation and biochemical modulation of the colonic environment.

Osmotic Action and Fluid Dynamics

The molecule acts as a non-absorbed solute, establishing an osmotic gradient across the intestinal wall. This physical process draws water into the colon lumen, significantly increasing the volume and fluidity of the contents, which alters the mechanical properties of the contents. This mechanical stretching of the colonic wall stimulates natural peristaltic reflexes, which drives the activation of peristaltic movement.

Fermentation and Ammonia Ion Trapping

Once in the colon, the drug is metabolized by native saccharolytic bacteria through fermentation, yielding osmotically active Short-Chain Fatty Acids (SCFAs). This localized production of acids results in a drop in colonic pH, which chemically converts diffusible NH3 into the non-absorbable, charged ammonium ion ( NH4^+), trapping it within the bowel, which limits its absorption into the systemic circulation.

Dosage and Administration Information

How to use Lactulak

Lactulak is typically available as an oral solution or syrup, defining the primary route of administration. The rectal route is also officially approved for specific, acute circumstances, where the solution is prepared as a retention enema. The medicine’s use is structured around two distinct regulatory dosing regimens:

Indication Initial Adult Dosing Regimen Frequency and Adjustment Logic
Bowel Regularity 15 to 30 mL ( 10 to 20 g) Typically administered once daily or in two divided doses; may take 24 to 48 hours for effect.
Systemic Imbalance 30 to 45 mL ( 20 to 30 g) Administered three or four times daily and systematically titrated to produce 2 to 3 soft stools daily.

For oral intake, the solution may be administered undiluted or may be mixed with water, fruit juice, or milk to improve palatability. If a single dose is utilized, official instructions specify that it should be taken at the same time each day, such as during breakfast. Regardless of the indication, official guidance recommends maintaining sufficient daily fluid intake of 1.5 to 2 litres throughout the course of treatment.

The duration of therapy is dependent on the context: it can be a short-term course for general bowel regularity, or it can require continuous long-term therapy for the prevention of recurring systemic imbalance episodes. Rectal administration mandates that the enema solution must be retained for 30 to 60 minutes and should not be used with alkaline cleansing agents.

Recent Clinical Evidence

Lactulak: Recent Clinical Evidence

Research Evidence for Bowel Regularity Support

The research into Lactulak’s use for chronic and habitual constipation primarily consists of Randomized Controlled Trials (RCTs) and Meta-analyses that combine findings from multiple trials. These studies were used in research exploring how symptoms change over time, typically tracking patients over short-term periods ranging from a few weeks up to about two months. The main outcomes studied relate to outcomes related to physical discomfort and the measurable function of the bowels. Researchers examined changes in stool frequency and stool consistency. Studies reported measurements of these factors when comparing Lactulak to a placebo or other agents. Studies also tracked patient-reported outcomes describing perceived discomfort. The existing evidence contributes to the broader evidence landscape for this condition. However, certainty remains low for long-term outcomes, as follow-up durations were limited in most main trials.

Research Evidence for Systemic Imbalance (Hepatic Encephalopathy)

For conditions involving periods of heightened symptoms related to advanced liver disease, research has explored the use of Lactulak through a large number of RCTs, with the evidence being consolidated through Systematic Reviews and Meta-analyses. Studies monitored clinical outcomes such as the clinical reversal of acute episodes, using standardized neurological criteria. They also tracked objective factors like changes in blood ammonia levels and monitored mortality rates. Findings indicate that this research provides context on how symptoms evolved in the observed populations, leading to its inclusion in many guidelines. The research contributes to the broader evidence landscape for conditions characterized by episodic manifestations.

Evidence in Specific Patient Populations and Uncertainty

Research examined how Lactulak performed across different age groups. Studies explored the use of the medicine in Children, including preschool-age groups, and in Older adults with chronic constipation. However, research so far indicates that data for certain groups remain insufficient. Several structural limitations and gaps are described in the existing research landscape. For certain outcomes, evidence quality varies across studies, sometimes due to differences in trial design. Additionally, researchers have noted variability in outcome definitions across different clinical trials. Study results reflect the specific conditions under which they were conducted, and research provides context but not individual predictions.

Key Studies & References

  1. Hepatic Encephalopathy in Chronic Liver Disease: 2014 Practice Guideline by AASLD and EASL
  2. Lactulose Solution, USP, 10 g/15 mL Solution: FDA Approved Labeling (via DailyMed)

Frequently Asked Questions (FAQ)

Common questions about Lactulak (FAQ)

Q: Do people use Lactulak for other reasons besides its main approved use?

A: Official documents list two distinct primary indications for this medicine. It is indicated to support bowel regularity and to manage complications associated with advanced liver disease, such as portal-systemic encephalopathy.


Q: How quickly should I expect Lactulak to start working?

A: For its use in supporting bowel regularity, official documents indicate that the desired effect may occur within 24 to 48 hours after administration, as the medicine requires time to work within the colon.


Q: Is it normal to feel bloated when first taking Lactulak?

A: Official labeling states that certain gastrointestinal effects are common, especially when first starting treatment. Flatulence (gas) and abdominal discomfort or cramping are expected effects that often occur during the first few days of treatment and are usually temporary.


Q: What should I do if I accidentally take too much Lactulak?

A: Taking excessive amounts of the solution can potentially lead to undesirable effects such as diarrhea and abdominal pain. Regulatory guidance indicates that reducing the dose or contacting a healthcare provider may be necessary if this occurs.


Q: Is Lactulak safe for use during pregnancy?

A: Studies conducted in animals have not indicated harm to the fetus. However, adequate human studies are not available. Regulatory guidance states that the medicine is to be used during pregnancy only if clearly needed and with caution.


Q: Is Lactulak generally appropriate for breastfeeding mothers?

A: It is not known if the medicine passes into human milk. Because of this uncertainty, official regulatory guidance states caution should be exercised when the solution is administered to a nursing woman.


Q: Can children or infants use Lactulak?

A: While usage in children is described in official labeling, regulatory documents state that very little information on its use in pediatric patients has been recorded overall. Use in infants and small children often requires specialized monitoring.


Q: Is Lactulak suitable for people with diabetes?

A: Regulatory documents state the medicine is to be used with caution by people with diabetes. This is because the solution contains small amounts of unabsorbed sugars, including galactose and lactose.


Q: Is there a known interaction between Lactulak and antibiotics?

A: Yes, certain anti-infective agents (antibiotics) may interact with the medicine. Regulatory labeling notes that drugs like neomycin may interfere with the colon bacteria necessary for the medicine’s required breakdown, potentially reducing its effectiveness.


Q: What is the consistency or taste of the liquid Lactulak formulation?

A: The solution is typically a clear to yellow/golden-yellow, viscous liquid (syrup consistency). It is usually described as unflavored but can be mixed with water, milk, or fruit juice to improve palatability.


Q: What are the signs of an allergic reaction to Lactulak?

A: Although the frequency is not known, the potential for hypersensitivity reactions is noted in official documents. These types of reactions may involve signs such as rash, itching, or hives (urticaria).


Q: Does Lactulak cause any stomach cramping?

A: Yes, official labeling indicates that abdominal discomfort, including cramping, is a known effect. This is typically temporary and may be most noticeable during the initial days of treatment.


Q: Can Lactulak affect my blood sugar levels?

A: Because the solution contains small amounts of sugars and is to be used with caution in people with diabetes, there is a potential to cause elevated blood sugar levels (hyperglycemia) in diabetic individuals, particularly when used at high doses.


Q: What happens if I miss a dose of Lactulak?

A: Official guidance indicates that if a dose is missed, skipping the missed dose and continuing with the regular schedule may be appropriate. It also states not to take a double dose to compensate for a missed one.


Q: Is it normal for the color of Lactulak to vary slightly?

A: Yes, official documents note that a normal darkening of color may occur when the product is stored under recommended conditions. This color change is characteristic of the solution and does not change its action or effectiveness.


Q: Does Lactulak contain any common allergens like gluten or lactose?

A: The solution contains small amounts of sugars that are not fully absorbed, including lactose (less than 1.2 g/15 mL) and galactose (less than 1.6 g/15 mL).


Q: Are there any specific lifestyle changes that are recommended while using Lactulak?

A: Official guidance indicates that maintaining sufficient daily fluid intake (typically 1.5 to 2 litres) throughout the course of treatment is important.


Q: What does official guidance say about using Lactulak before surgery?

A: Regulatory warnings describe a theoretical hazard during specific colon procedures involving electrocautery due to the accumulation of hydrogen gas. A thorough bowel cleansing with a non-fermentable solution may be recommended before such procedures.


Q: Can Lactulak be used for short-term relief?

A: The duration of therapy is dependent on the specific context of use. The solution may be used as a short-term course for general bowel regularity, or it may require continuous long-term use for other indications.


Q: Are there restrictions on driving or operating machinery while using Lactulak?

A: Regulatory documents indicate that there are no known effects on the ability to drive or operate machinery while using this medicine.

How should Lactulak be stored and disposed of?

How to Store and Dispose of Lactulak Solution

Lactulak solution must be stored at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F). The solution must be kept in a tightly closed container and protected from direct light and excessive heat, as temperatures above 30 C may cause extreme darkening and turbidity, making the product unusable.


Temperature and Container Restrictions

Requirement Status
Do Not Freeze Mandatory
Keep Out of Reach of Children Mandatory
Dispense in Light-Resistant Container Mandatory

It is required to avoid subfreezing temperatures and do not freeze the solution. The container must have a child-resistant closure and be stored out of the reach of children. Unused or expired solution must be disposed of in accordance with local requirements and should not be kept.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Lactulak found in:

A-Z Index: